Top

Published in:

01-06-2015 | Research Article

Nicotinamide induces apoptosis of F9 mouse teratocarcinoma stem cells by downregulation of SATB1 expression

Authors: Yan Zhang, Haibo Wu, Man Zhang, Yali Jiang, Weiwei Zhuo, Yong Zhang, Song Hua

Published in: Tumor Biology | Issue 6/2015

Abstract

The aim of this study was to decide whether nicotinamide (NA) could induce apoptosis of F9 mouse teratocarcinoma stem cells (MF9) by downregulation of special AT-rich sequence binding protein 1 (SATB1) expression. We used different concentrations of NA (0, 1.5, 2, and 2.5 mmol/L) to treat MF9 cells and analyze SATB1 expression by RT-qPCR and Western blotting; in addition, the cell proliferation was detected in a microplate reader with Cell Counting Kit-8 (CCK-8), and the cell cycle and apoptosis were analyzed using flow cytometry. We found that the expression of SATB1 was decreased significantly in NA-treated groups than in the control group, and its expression level was inversely related to the NA concentration. In addition, CCK-8 analysis showed that NA significantly inhibited the proliferation of MF9 cells, and flow cytometry showed that NA blocked MF9 cells to G1 phase and significantly promoted apoptosis in any treated groups. To confirm the results, we constructed small interference RNA (siRNA) targeting at mouse SATB1 and transferred into MF9 cells. The results indicated that the expression of SATB1 in both mRNA and protein levels was significantly decreased after cells transferred with siRNA sequence for 48 h, the proliferation of MF9 cells was significantly inhibited, and most of MF9 cells were blocked at G1 phase, and the apoptosis rate was increased obviously. The results showed that NA could inhibit the proliferation and induce apoptosis of MF9 cells. These findings might be used as an efficient candidate for teratocarcinoma therapy.

Sonee M, Martens JR, Mukherjee SK. Nicotinamide protects HCN2 cells from the free radical generating toxin, tertiary-butylhydroperoxide (t-BuOOH). Neurotox Res. 2002;4:595–9.CrossRefPubMed

Jin J, Lee KB, Park SY, Jang JJ. Nicotinamide inhibits hepatic fibrosis by suppressing DNA synthesis and enhancing apoptosis of hepatic stellate cells. Virchows Arch. 2011;458:689–96.CrossRefPubMed

Saldeen J, Tillmar L, Karlsson E, Welsh N. Nicotinamide-and caspase-mediated inhibition of poly(ADP-ribose) polymerase are associated with p53-independent cell cycle (G2) arrest and apoptosis. Mol Cell Biochem. 2003;243:113–22.CrossRefPubMed

Audrito V, Vaisitti T, Rossi D, Gottardi D, D’Arena G, Laurenti L, et al. Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res. 2011;71:4473–83.CrossRefPubMed

Fernandes CA, Fievez L, Ucakar B, Neyrinck AM, Fillee C, Huaux F, et al. Nicotinamide enhances apoptosis of G(M)-CSF-treated neutrophils and attenuates endotoxin-induced airway inflammation in mice. Am J Physiol Lung Cell Mol Physiol. 2011;300:L354–61.CrossRefPubMed

Luo JY, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 2001;107:137–48.CrossRefPubMed

Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 2004;303:2011–5.CrossRefPubMed

Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell. 2004;116:551–63.CrossRefPubMed

Hoane MR, Kaplan SA, Ellis AL. The effects of nicotinamide on apoptosis and blood-brain barrier breakdown following traumatic brain injury. Brain Res. 2006;1125:185–93.CrossRefPubMed

10.

Dickinson LA, Joh T, Kohwi Y, Kohwi-Shigematsu T. A tissue-specific MAR/SAR DNA-binding protein with unusual binding site recognition. Cell. 1992;70:631–45.CrossRefPubMed

11.

Shen ZH, Zeng YM, Guo JL, Wu YX, Jiang XF, Ding R, et al. Over-expression of the special AT rich sequence binding protein 1 (SATB1) promotes the progression of nasopharyngeal carcinoma: association with EBV LMP-1 expression. J Transl Med. 2013. doi:10.1186/1479-5876-11-217.

12.

Chu SH, Ma YB, Feng DF, Zhang H, Qiu JH, Zhu ZA, et al. Relationship between SATB1 expression and prognosis in astrocytoma. J Clin Neurosci. 2013;20:543–7.CrossRefPubMed

13.

Meng WJ, Yan H, Zhou B, Zhang W, Kong XH, Wang R, et al. Correlation of SATB1 overexpression with the progression of human rectal cancer. Int J Colorectal Dis. 2012;27:143–50.CrossRefPubMed

14.

Endo K, Shackelford J, Aga M, Yoshizaki T, Pagano JS. Upregulation of special AT-rich-binding protein 1 by Epstein–Barr virus latent membrane protein 1 in human nasopharyngeal cells and nasopharyngeal cancer. J Gen Virol. 2013;94:507–13.CrossRefPubMedPubMedCentral

15.

Iorns E, Hnatyszyn HJ, Seo P, Clarke J, Ward T, Lippman M. The role of SATB1 in breast cancer pathogenesis. J Natl Cancer Inst. 2010;102:1284–96.CrossRefPubMed

16.

Patani N, Jiang W, Mansel R, Newbold R, Mokbel K. The mRNA expression of SATB1 and SATB2 in human breast cancer. Cancer Cell Int. 2009. doi:10.1186/1475-2867-9-18.PubMedPubMedCentral

17.

Fang FX, Hou ZB, Dai XZ, Chen C, Ge J, Shen H, et al. Special AT-rich sequence-binding protein 1 promotes cell growth and metastasis in colorectal cancer. World J Gastroenterol. 2013;19:2331–9.CrossRefPubMedPubMedCentral

18.

Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature. 2008;452:187–93.CrossRefPubMed

19.

Mao LJ, Yang CH, Wang JQ, Li W, Wen RM, Chen JC, et al. SATB1 is overexpressed in metastatic prostate cancer and promotes prostate cancer cell growth and invasion. J Transl Med. 2013. doi:10.1186/1479-5876-11-111.

20.

Huang B, Zhou HL, Wang XD, Liu ZL. Silencing SATB1 with siRNA inhibits the proliferation and invasion of small cell lung cancer cells. Cancer Cell Int. 2013. doi:10.1186/1475-2867-13-8.

21.

Zhang Y, Tian X, Ji H, Guan X, Xu W, Dong B, et al. Expression of SATB1 promotes the growth and metastasis of colorectal cancer. Plos One. 2014. doi:10.1371/journal.pone.0100413.

22.

Nodin B, Hedner C, Uhlén M, Jirström K. Expression of the global regulator SATB1 is an independent factor of poor prognosis in high grade epithelial ovarian cancer. J Ovarian Res. 2012. doi:10.1186/1757-2215-5-24.

23.

Han S, Xia J, Qin X, Han S, Wu A. Phosphorylated SATB1 is associated with the progression and prognosis of glioma. Cell Death Dis. 2013. doi:10.1038/cddis.2013.433.

24.

Cheng C, Lu XM, Wang GB, Zhang L, Shu XJ, Zhu SK, et al. Expression of SATB1 and heparanase in gastric cancer and its relationship to clinico-pathologic features. APMIS. 2010;118:855–63.CrossRefPubMed

25.

Selinger CI, Cooper WA, Al-Sohaily S, Mladenova DN, Pangon L, Kennedy CW, et al. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer. J Thorac Oncol. 2011;6:1179–89.CrossRefPubMed

26.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-△△Ct method. Methods. 2001;25:402–8.CrossRefPubMed

27.

Zhao XD, Ji WY, Zhang W, He LX, Yang J, Liang HJ, et al. Overexpression of SATBl in laryngeal squamous cell carcinoma. ORL. 2010;72:1–5.CrossRefPubMed

28.

Chu SH, Ma YB, Feng DF, Zhang H, Zhu ZA, Li ZQ, et al. Upregulation of SATB1 is associated with the development and progression of glioma. J Transl Med. 2012. doi:10.1186/1479-5876-10-149.PubMedPubMedCentral

29.

Chen H, Takahara M, Oba J, Xie L, Chiba T, Takeuchi S, et al. Clinicopathologic and prognostic significance of SATB1 in cutaneous malignant melanoma. J Dermatol Sci. 2011;64:39–44.CrossRefPubMed

30.

Jafary H, Ahmadian S, Soleimani M. The enhanced apoptosis and antiproliferative response to combined treatment with valproate and nicotinamide in MCF-7 breast cancer cells. Tumor Biol. 2014;35:2701–10.CrossRef

31.

Wang T, Cui H, Ma N, Jiang YH. Nicotinamide-mediated inhibition of SIRT1 deacetylase is associated with the viability of cancer cells exposed to antitumor agents and apoptosis. Oncol Lett. 2013;6:600–4.PubMedPubMedCentral

32.

Ogata S, Takeuchi M, Fujita H, Shibata K, Okumura K, Taguchi H. Apoptosis induced by nicotinamide-related compounds and quinolinic acid in HL-60 Cells. Biosci Biotechnol Biochem. 2000;64:327–32.CrossRefPubMed

33.

Tu W, Luo M, Wang Z, et al. Upregulation of SATB1 promotes tumor growth and metastasis in liver cancer. Liver Int. 2012;32:1064–78.CrossRefPubMed

34.

Han B, Luan L, Xu ZQ, Wu B. Expression and biological roles of SATB1 in human bladder cancer. Tumor Biol. 2013;34:2943–9.CrossRef

35.

Chu SH, Zhou ZM, Feng DF, Ma YB. Inhibition of human glioma U251 cells growth in vitro and in vivo by hydroxyapatite nanoparticle-assisted delivery of short hairpin RNAs against SATB1. Mol Biol Rep. 2014;41:977–86.CrossRefPubMed

Title: Nicotinamide induces apoptosis of F9 mouse teratocarcinoma stem cells by downregulation of SATB1 expression
Authors: Yan Zhang
Haibo Wu
Man Zhang
Yali Jiang
Weiwei Zhuo
Yong Zhang
Song Hua
Publication date: 01-06-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 6/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3073-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2015

A novel tumor suppressor gene in basal cell carcinoma: inhibition of growth factor-2

Clinical significance of Sam68 expression in endometrial carcinoma

Autophagy and its function in radiosensitivity

FBW7 increases drug sensitivity to cisplatin in human nasopharyngeal carcinoma by downregulating the expression of multidrug resistance-associated protein

Overexpression of CUGBP1 is associated with the progression of non-small cell lung cancer

Simvastatin downregulates expression of TGF-βRII and inhibits proliferation of A549 cells via ERK

Keynote webinar | Spotlight on antibody–drug conjugates in cancer